MMP2-IN-1

MMP2-IN-1 is a moderate potenet MMP2 inhibitor with IC 50 of 6.8 µM. MMP2-IN-1 exhibits remarkable antiproliferative activity in certain cancer cells by arresting the cell cycle and inducing apoptosis In Vitro MMP2-IN-1 (compound 4a) (0-10 μM; 74 hours) exhibits IC 50 values of 0.07 μM, 0.11 μM, and 0.18 μM against MDA-MB-231, A549, and HeLa cancer cells, respectively, and over 10 μM in Hep 5G cells. MMP2-IN-1 (10 μM; 24 hours) induces cell cycle arrest in the S phase. MMP2-IN-1 (0.01 μM, 0.1 μM, 1 μM and 10 μM; 24 hours) induces a dose-dependent increment in early-and late-stage apoptosis of MDA-MB-231 cells, and increased the early-stage apoptosis percentage from 4.66% to 10.9% at 10 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay Cell Line: MDA-MB-231, A549, HeLa and Hep 5G cellsConcentration: 0-10 μM Incubation Time: 74 hours Result: Exhibited IC 50 values of 0.07 μM, 0.11 μM, and 0.18 μM against MDA-MB-231, A549, and HeLa cancer cells, respectively, and over 10 μM in Hep 5G cells. Cell Cycle Analysis Cell Line: MDA-MB-231Concentration: 10 μM Incubation Time: 24 hours Result: Induced cell cycle arrest in the S phase. Apoptosis Analysis Cell Line: MDA-MB-231Concentration: 0.01 μM, 0.1 μM, 1 μM and 10 μM Incubation Time: 24 hours Result: Induced a dose-dependent increment in early-and late-stage apoptosis of MDA-MB-231 cells, and increased the early-stage apoptosis percentage from 4.66% to 10.9% at 10 μM. In Vivo MMP2-IN-1 (100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg; IP, single) causes 0%, 30%, 50% and 60% mortality rate at dosing 100 mg/kg, 150 mg/kg, 200 mg/kg and 250 mg/kg respectively . MMP2-IN-1 (10 mg/kg; IP, daily, for 14 days) significantly inhibits tumor growth in metastatic 4T1 murine breast cancer model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Kunming mice (n = 10, half male and half female) Dosage: 100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg Administration: IP, single Result: No mortality occurred after administration of 100 mg/kg, and the mortality rate was 30%, 50% and 60% at dosing 150 mg/kg, 200 mg/kg, 250 mg/kg respectively. Animal Model: Orthotopic 4T1 tumor-bearing mice Dosage: 10 mg/kg Administration: IP, daily, for 14 days Result: Significantly inhibited tumor growth in metastatic 4T1 murine breast cancer model. Form:Solid IC50& Target:MMP2 6.8 μM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet